Rheumatoid Arthritis Clinical Trial
— FASTAOfficial title:
Effects of a Clinical Dietary Intervention During Inpatient Treatment (Modified Fasting in Metabolic Syndrome, Osteoarthritis of the Hip or Knee, Rheumatoid Arthritis and Fibromyalgia)
Verified date | May 2021 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of the study is a scientific and prospective documentation of the clinical effects of an inpatient treatment at the Immanuel Hospital of Berlin, in the department for complementary and integrative medicine, with the use of a modified fasting regime. A pre- and post- as well as group comparisons are planned. Patients that are admitted to the inpatient department for metabolic syndrome, osteoarthritis of the hip or knee, rheumatoid arthritis and fibromyalgia will be enrolled in the study.
Status | Active, not recruiting |
Enrollment | 500 |
Est. completion date | March 1, 2022 |
Est. primary completion date | March 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - The patient is consents to participating in the trial during the first 24h of his or her stay in the inpatient naturopathic department of the Immanuel Hospital. - Written informed consent is given - The referral diagnosis is one of the following: diabetes mellitus type 2/metabolic syndrome, osteoarthritis of the hip, osteoarthritis of the knee, rheumatoid arthritis, fibromyalgia. Exclusion Criteria: - Language barries to understanding the instructions of the study personnel - Dementia or other strong cognitive impairment - Pregnant or lactating women - Taking part in another study at the same time |
Country | Name | City | State |
---|---|---|---|
Germany | Immanuel Hospital | Berlin-Wannsee | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fibromyalgia Impact Questionnaire (FIQ) | Questionnaire; The FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus. | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Primary | Disease Activity Score 28 (DAS 28) | Questionnaire with Clinical Examination; Change from Baseline in the DAS-28, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Primary | Health Assessment Questionnaire (HAQ) | Questionnaire; Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Primary | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Questionnaire consisting of 24 items divided into 3 subscales: Pain (5items), Stiffness (2 items), Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).
The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher values meaning a higher grade of disability. |
Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Primary | Summary of Diabetes Self Care Activities Measure (SDSCA) | Questionnaire; 11 items with each item scored on a scale of 0-7. | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Secondary | Pain on Visual Analogue Scale (VAS) | Questionnaire | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Secondary | Hospital Anxiety and Depression Scale (HADS) | Questionnaire; HADS: Assessing full scale, range 0-42, lower score meaning a better outcome | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Secondary | Perceived Stress Scale (PSS) | Questionnaire; Change from Baseline in the PSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress. | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Secondary | Quality of Life (WHO-5) | Questionnaire; Change from Baseline in the WHO-5, range from 0 to 100 % while higher values meaning a higher grade of well-being | Change Baseline, 2 weeks, 3 months, 6 months, 12 months | |
Secondary | Body-Mass-Index (BMI) | Anthropometry | Change Baseline, 2 weeks | |
Secondary | Blood pressure | Measuring systolic and diastolic blood pressure in mmHg | Change Baseline, 2 weeks | |
Secondary | 24h-Blood pressure | Measuring systolic and diastolic blood pressure with Device "Mobil-O-Graph" | Change Baseline, 2 weeks | |
Secondary | Blood count | Laboratory test | Change Baseline, 2 weeks | |
Secondary | Glomerular filtration rate (GFR) | Laboratory test | Change Baseline, 2 weeks | |
Secondary | Blood lipids | triglycerides (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L), fasting glucose (mmol/L) | Change Baseline, 2 weeks | |
Secondary | CRP | CRP in milligram per liter (mg/L) | Change Baseline, 2 weeks | |
Secondary | Liver enzymes (GOT, GPT) | Hepatic transaminases (GPT, GOT in U/L) | Change Baseline, 2 weeks | |
Secondary | Stepcounter | With Device "Everion" | Change Baseline, 2 weeks | |
Secondary | Heart Rate Variability | With Device "Faros 180" | Change Baseline, 2 weeks | |
Secondary | Heart Rate | With Device "Everion" | Change Baseline, 2 weeks | |
Secondary | Blood Oxygenation | With Device "Everion" | Change Baseline, 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |